153P - Predictive markers of survival in patients with pulmonary metastases and malignant pleural effusion

Date 07 May 2017
Event ELCC 2017
Session Poster Display Session
Topics Thoracic Malignancies
Presenter Franco Lumachi
Citation Annals of Oncology (2017) 28 (suppl_2): ii52-ii55. 10.1093/annonc/mdx094
Authors F. Lumachi1, S.M. Basso2, R. Tozzoli3, A. Del Conte4, U. Zuccon5, P. Ubiali6
  • 1Department Of Surgery, Oncology & Gastroenterology, University of Padua, School of Medicine, 35128 - Padova/IT
  • 2Department Of Surgery, S. Maria degli Angeli Hospital, Pordenone/IT
  • 3Department Of Laboratory Medicine, Clinical Pathology Laboratory, S. Maria degli Angeli Hospital, Pordenone/IT
  • 4Mecical Oncology, S. Maria degli Angeli Hospital, 33170 - Pordenone/IT
  • 5Pneumology, S. Maria degli Angeli Hospital, 33170 - Pordenone/IT
  • 6Department Of Surgery, S. Maria degli Angeli Hospital, 33170 - Pordenone/IT

Abstract

Background

Lung metastases (LMs) can be identified in up to 30-50% of all cancer patients, and represent the result of metastatic spread to the lungs from the several cancers. The presence of LMs seriously affects overall survival (OS), and the onset of pleural effusion further reduces the life expectancy of the patients. The aim of this retrospective study was to evaluate the usefulness of carcinoembryonic antigen (CEA), lactate dehydrogenase (LDH), and C-reactive protein (CRP) measurement in the pleural fluid of patients with LMs and malignant pleural effusion (MPE).

Methods

The medical records of 22 patients (median age 68 years, range 46-86) with LMs (mainly from breast, urinary tract, and colorectal cancers) and MPE were analyzed. There were 13 (59.1%) males and 9 (40.9%) females. All patients underwent video-assisted thoracoscopic (VAT)-assisted thoracentesis and subsequent pleural fluid examination, including CEA, LDH, and CRP, which were measured using a chemiluminescent (CLIA) immunoassay (sandwich CLIA with native CEA coated to magnetic microbeads), a spectrophotometric assay (L-lactate as substrate), and an immunonephelometric assay (polystyrene particles coated with anti-human CRP monoclonal antibodies), respectively.

Results

The OS was 6.7±5.2 months (range 1-23 months), and the levels of pleural markers were 10.4±21.6 ng/mL (CEA), 418.4±342.9 U/L (LDH), and 6.2±9.1 mg/L (CRP). No relationship was found between OS and the age of the patients (R = 0.14, p = 0.542), LDH (R=-0.31, p = 0.169) or CRP (R=-0.33, p = 0.136). There was a significant direct correlation between OS and CEA (R = 0.66, p = 0.0007). The relative regression line equations are reported in the table.rnTable: 153Prn

rnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrn
ParameterRegression line equation
Age of the patientsOS = 63.323797651973 + 0.23725477330884 age
CEAOS = 2.0616207417742-4.4634344843623 CEA
LDHOS = 470.3738751303-20.900941750959 LDH
CRPOS = 12.210673177537-0.84687826996861
rn

Conclusions

In patients with MPE and LMs, only CEA pleural levels significantly related to OS, and can be considered a useful predictive factor. Further studies will eventually confirm our results.

Clinical trial identification

Legal entity responsible for the study

Università degli Studi di Padova

Funding

Università degli Studi di Padova

Disclosure

All authors have declared no conflicts of interest.